DDIT3 and cancer: One of the possible reasons for this difference is that secondary cancers in patients with HCL may primarily result from the immunosuppressive effects caused by purine analogs, whereas in patients with DLBCL, secondary cancers are more likely driven by direct DNA damage from multi-agent chemotherapy such as R-CHOP, leading to the earlier development of secondary malignancies.